RTA 402 Phase 2 Clinical Trial (A Randomized, Double-blind, Placebo-controlled Clinical Trial in Patients With Chronic Kidney Disease and Type 2 Diabetes).

Trial Profile

RTA 402 Phase 2 Clinical Trial (A Randomized, Double-blind, Placebo-controlled Clinical Trial in Patients With Chronic Kidney Disease and Type 2 Diabetes).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Bardoxolone methyl (Primary)
  • Indications Diabetic nephropathies
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TSUBAKI study
  • Sponsors Kyowa Hakko Kirin
  • Most Recent Events

    • 12 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 14 Nov 2016 According to a Reata Pharmaceuticals Media Release, factors and mitigation strategy of the BEACON trial has been adopted in this trial.
    • 14 Nov 2016 Results published in the Reata Pharmaceuticals Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top